發(fā)布時間：2018-07-12 11:31

  本文選題：肺腫瘤 + PDTX模型��； 參考：《中國肺癌雜志》2017年10期

【摘要】：當前隨著腫瘤分子生物學及基因組學的發(fā)展,人們已經(jīng)認識到同一瘤種在不同個體間其生物學特征、分子分型以及對藥物干預的反應性都存在巨大的異質性,這種個體化差異是導致腫瘤治療過程中同病同治而不同效的重要原因,因此為了實現(xiàn)真正的腫瘤個體化精準治療,腫瘤研究領域提出了一個新的概念即人源腫瘤組織異種移植模型(patient derived tumor xenograft,PDTX);該模型可以真實地反映患者腫瘤組織的生物學特性以及藥物療效,是研究個體化治療、藥物耐藥以及新藥研發(fā)的重要手段,已被運用包括肺癌在內多個瘤種的臨床診治過程中。本文就當前肺癌PDTX模型的研究進展進行綜述。
[Abstract]:At present, with the development of tumor molecular biology and genomics, it has been recognized that the biological characteristics, molecular typing and reactivity to drug intervention of the same tumor species have great heterogeneity among different individuals. This individualized difference is an important reason for the difference in the efficacy of the same disease in the course of cancer treatment, so in order to achieve true individualized and accurate treatment of the tumor, A new concept, (patient derived tumor xenograft PDTX, has been put forward in the field of tumor research, which can reflect the biological characteristics and drug efficacy of tumor tissue in patients, and is a kind of individualized therapy. Drug resistance and the important means of new drug development have been used in the clinical diagnosis and treatment of many kinds of tumors, including lung cancer. In this paper, the research progress of PDTX model for lung cancer is reviewed.
【作者單位】： 上海長征醫(yī)院腫瘤科;
【基金】：上海市青年科技揚帆計劃(No.17YF1425200) 上海長征醫(yī)院青年啟動基金(No.2015CZQN07) 國家自然科學基金(No.81702249) 上海市衛(wèi)生計生委基金(No.201540174)資助~~
【分類號】：R734.2
，

本文編號：2117013